NFE2L2 and Hepatic fibrosis: Some studies have revealed that in various obesity and insulin-resistant models, NRF2 activation can reverse insulin resistance, inhibit the steatosis of hepatocytes, and attenuate liver fibrosis (Lee et al., 2014; Yamada et al., 2018; Li et al., 2020).